Post transplant lymphoproliferative disorder: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 10: Line 10:


==Historical Perspective==
==Historical Perspective==
*Post transplant lymphoproliferative disorder was first discovered by Denis Parsons Burkitt, an Irish physician, in 1965.
*Post transplant lymphoproliferative disorder was first discovered by Denis Parsons Burkitt, an Irish physician, in 1965.<ref name="wiki">Post transplant lymphoproliferative disorder. Wikipedia. https://en.wikipedia.org/wiki/Post-transplant_lymphoproliferative_disorder Accessed on May 23, 2016 </ref>


==Classification==
==Classification==
*Post transplant lymphoproliferative disorder may be classified according to World Health Organization (WHO) classification system, into 4 subtypes:
*Post transplant lymphoproliferative disorder may be classified according to World Health Organization (WHO) classification system, into 4 subtypes:<ref name="wiki">Post transplant lymphoproliferative disorder. Wikipedia. https://en.wikipedia.org/wiki/Post-transplant_lymphoproliferative_disorder Accessed on May 23, 2016 </ref>
:*Early hyperplastic lesions
:*Early hyperplastic lesions
:*Polymorphic lesions
:*Polymorphic lesions
Line 48: Line 48:


===Age===
===Age===
*Post transplant lymphoproliferative disorder is more commonly observed among young patients.  
*Post transplant lymphoproliferative disorder is more commonly observed among young patients.<ref name="wiki">Post transplant lymphoproliferative disorder. Wikipedia. https://en.wikipedia.org/wiki/Post-transplant_lymphoproliferative_disorder Accessed on May 23, 2016 </ref>
   
   
===Gender===
===Gender===
Line 64: Line 64:
*If left untreated, patients with post transplant lymphoproliferative disorder may progress to develop organ failure.  
*If left untreated, patients with post transplant lymphoproliferative disorder may progress to develop organ failure.  
*The most common complication of post transplant lymphoproliferative disorder is fatal infection.  
*The most common complication of post transplant lymphoproliferative disorder is fatal infection.  
*Prognosis is generally poor, and the 5-year survival rate of patients with post transplant lymphoproliferative disorder is approximately 37- 61%
*Prognosis is generally poor, and the 5-year survival rate of patients with post transplant lymphoproliferative disorder is approximately 37- 61%.<ref name="wiki">Post transplant lymphoproliferative disorder. Wikipedia. https://en.wikipedia.org/wiki/Post-transplant_lymphoproliferative_disorder Accessed on May 23, 2016 </ref>


== Diagnosis ==
== Diagnosis ==

Revision as of 22:07, 23 May 2016

WikiDoc Resources for Post transplant lymphoproliferative disorder

Articles

Most recent articles on Post transplant lymphoproliferative disorder

Most cited articles on Post transplant lymphoproliferative disorder

Review articles on Post transplant lymphoproliferative disorder

Articles on Post transplant lymphoproliferative disorder in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Post transplant lymphoproliferative disorder

Images of Post transplant lymphoproliferative disorder

Photos of Post transplant lymphoproliferative disorder

Podcasts & MP3s on Post transplant lymphoproliferative disorder

Videos on Post transplant lymphoproliferative disorder

Evidence Based Medicine

Cochrane Collaboration on Post transplant lymphoproliferative disorder

Bandolier on Post transplant lymphoproliferative disorder

TRIP on Post transplant lymphoproliferative disorder

Clinical Trials

Ongoing Trials on Post transplant lymphoproliferative disorder at Clinical Trials.gov

Trial results on Post transplant lymphoproliferative disorder

Clinical Trials on Post transplant lymphoproliferative disorder at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Post transplant lymphoproliferative disorder

NICE Guidance on Post transplant lymphoproliferative disorder

NHS PRODIGY Guidance

FDA on Post transplant lymphoproliferative disorder

CDC on Post transplant lymphoproliferative disorder

Books

Books on Post transplant lymphoproliferative disorder

News

Post transplant lymphoproliferative disorder in the news

Be alerted to news on Post transplant lymphoproliferative disorder

News trends on Post transplant lymphoproliferative disorder

Commentary

Blogs on Post transplant lymphoproliferative disorder

Definitions

Definitions of Post transplant lymphoproliferative disorder

Patient Resources / Community

Patient resources on Post transplant lymphoproliferative disorder

Discussion groups on Post transplant lymphoproliferative disorder

Patient Handouts on Post transplant lymphoproliferative disorder

Directions to Hospitals Treating Post transplant lymphoproliferative disorder

Risk calculators and risk factors for Post transplant lymphoproliferative disorder

Healthcare Provider Resources

Symptoms of Post transplant lymphoproliferative disorder

Causes & Risk Factors for Post transplant lymphoproliferative disorder

Diagnostic studies for Post transplant lymphoproliferative disorder

Treatment of Post transplant lymphoproliferative disorder

Continuing Medical Education (CME)

CME Programs on Post transplant lymphoproliferative disorder

International

Post transplant lymphoproliferative disorder en Espanol

Post transplant lymphoproliferative disorder en Francais

Business

Post transplant lymphoproliferative disorder in the Marketplace

Patents on Post transplant lymphoproliferative disorder

Experimental / Informatics

List of terms related to Post transplant lymphoproliferative disorder

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Synonyms and keywords: PTLD;

Overview

Post-transplant lymphoproliferative disorder (also known as PTLD) is defined as a B-cell proliferation due to therapeutic immunosuppression after organ transplantation. Patients with post-transplant lymphoproliferative disorder may develop infectious mononucleosis-like lesions or polyclonal polymorphic B-cell hyperplasia. In some cases, B-cells may undergo mutations which will render them malignant, giving rise to a lymphoma. The malignant cell clone can become the dominant proliferating cell type, leading to a group of B cell lymphomas occurring in immunosuppressed patients following organ transplant. Post transplant lymphoproliferative disorder arises from germinal center or post-germinal center B cells (B-PTLD), which are normally involved the production of antibodies and durable memory B cells. Post transplant lymphoproliferative disorder was first discovered by Denis Parsons Burkitt, an Irish physician, in 1965.[1] According to World Health Organization (WHO) classification system, post transplant lymphoproliferative disorder may be classified into 4 subtypes: early hyperplastic lesions, polymorphic lesions, monomorphic lesions, and classic Hodgkin-type lymphomas. Post transplant lymphoproliferative disorder is very rare, and the prevalence of post transplant lymphoproliferative disorder remains unknown. Post transplant lymphoproliferative disorder is more commonly observed among young patients. The medical treatment for post transplant lymphoproliferative disorder, includes: immunosuppression, antiviral therapy, interferon alpha therapy, CD20 antibody therapy, and chemotherapy.[1]

Historical Perspective

  • Post transplant lymphoproliferative disorder was first discovered by Denis Parsons Burkitt, an Irish physician, in 1965.[1]

Classification

  • Post transplant lymphoproliferative disorder may be classified according to World Health Organization (WHO) classification system, into 4 subtypes:[1]
  • Early hyperplastic lesions
  • Polymorphic lesions
  • Monomorphic lesions
  • Classic Hodgkin-type lymphomas

Pathophysiology

  • Post transplant lymphoproliferative disorder arises from germinal center or post-germinal center B cells (B-PTLD), which are normally involved the production of antibodies and durable memory B cells.
  • The pathogenesis of post transplant lymphoproliferative disorder is characterized by the production of interleukin-10.[2]
  • Resemblance to large cell lymphomas
  • The overexpression of bcl-2 has been associated with the development of post transplant lymphoproliferative disorder.[2]
  • On gross pathology, characteristic findings of post transplant lymphoproliferative disorder, include:[2]
  • Resemblance to large cell lymphomas
  • No remarkable findings
  • On microscopic histopathological analysis, characteristic findings of post transplant lymphoproliferative disorder, include:[2]
  • Resemblance to large cell lymphomas
  • Large lymphoid cells with a diameter (2x a resting lymphocyte)

Causes

  • The most common causes of post transplant lymphoproliferative disorder is Epstein-Barr virus.[3]

Differentiating Post Transplant Lymphoproliferative Disorder from Other Diseases

  • Post transplant lymphoproliferative disorder must be differentiated from other diseases that cause fatigue, weight-loss, and fever, such as:[1]

Epidemiology and Demographics

  • Post transplant lymphoproliferative disorder is very rare.
  • The prevalence of post transplant lymphoproliferative disorder remains unknown.

Age

  • Post transplant lymphoproliferative disorder is more commonly observed among young patients.[1]

Gender

  • Females are slightly more affected with post transplant lymphoproliferative disorder than men.

Race

  • There is no racial predilection for post transplant lymphoproliferative disorder.

Risk Factors

  • The most common risk factors in the development of post transplant lymphoproliferative disorder is B cell neoplasm associated with Epstein-Barr infection.

Natural History, Complications and Prognosis

  • The majority of patients with post transplant lymphoproliferative disorder are symptomatic at the time of diagnosis.
  • Early clinical features include fatigue, fever, and weight-loss.
  • If left untreated, patients with post transplant lymphoproliferative disorder may progress to develop organ failure.
  • The most common complication of post transplant lymphoproliferative disorder is fatal infection.
  • Prognosis is generally poor, and the 5-year survival rate of patients with post transplant lymphoproliferative disorder is approximately 37- 61%.[1]

Diagnosis

Symptoms

  • Post transplant lymphoproliferative disorder is usually asymptomatic.[3]
  • Symptoms of post transplant lymphoproliferative disorder may include the following:

Physical Examination

  • Patients with post transplant lymphoproliferative disorder usually appear pale and malnourished.[3]
  • Physical examination may be remarkable for:
  • Swelling in the lymph nodes in the neck or underarms
  • Fever
  • Night sweats
  • Unexplained weight loss

Laboratory Findings

  • There are no specific laboratory findings associated with post transplant lymphoproliferative disorder.[3]

Imaging Findings

  • There are no imaging findings associated with post transplant lymphoproliferative disorder.

Treatment

Medical Therapy

  • The medical treatment for post transplant lymphoproliferative disorder, includes: [4]
  • Immunosuppression
  • Antiviral therapy
  • Interferon alpha therapy
  • CD20 antibody therapy
  • Chemotherapy
  • Post-transplant lymphoproliferative disorder may regress spontaneously on reduction or cessation of immunosuppressant medication anti-viral therapy.

Surgery

  • Surgery is not recommended for patients with post transplant lymphoproliferative disorder.[3]

Prevention

  • There are no primary preventive measures available for post transplant lymphoproliferative disorder.

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Post transplant lymphoproliferative disorder. Wikipedia. https://en.wikipedia.org/wiki/Post-transplant_lymphoproliferative_disorder Accessed on May 23, 2016
  2. 2.0 2.1 2.2 2.3 Post transplant lymphoproliferative disorder. Libre Pathology. https://librepathology.org/wiki/Post-transplant_lymphoproliferative_disorder Accessed on May 23, 2016
  3. 3.0 3.1 3.2 3.3 3.4 Taylor AL, Marcus R, Bradley JA (2005). "Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation". Crit. Rev. Oncol. Hematol. 56 (1): 155–67. doi:10.1016/j.critrevonc.2005.03.015. PMID 15979320.
  4. BioMed Central. EBV-associated post-transplantation B-cell lymphoproliferative disorder following allogenic stem cell transplantation for acute lymphoblastic leukaemia: tumor regression after reduction of immunosuppression - a case report. https://diagnosticpathology.biomedcentral.com/articles/10.1186/1746-1596-5-21 Accessed on May 23, 2016